CrossRef Text and Data Mining
Result of CrossRef Text and Data Mining Search is the related articles with entitled article. If you click link1 or link2 you will be able to reach the full text site of selected articles; however, some links do not show the full text immediately at now. If you click CrossRef Text and Data Mining Download icon, you will be able to get whole list of articles from literature included in CrossRef Text and Data Mining.
A Single Arm, Phase II Study of Simvastatin Plus XELOX and Bevacizumab as First-Line Chemotherapy in Metastatic Colorectal Cancer Patients
Youjin Kim, Tae Won Kim, Sae Won Han, Joong Bae Ahn, Seung Tae Kim, Jeeyun Lee, Joon Oh Park, Young Suk Park, Ho Yeong Lim, Won Ki Kang
Cancer Research and Treatment. 2019;51(3):1128-1134.   Published online 2018 November 21    DOI: https://doi.org/10.4143/crt.2018.379

Excel Download

A Single Arm, Phase II Study of Simvastatin Plus XELOX and Bevacizumab as First-Line Chemotherapy in Metastatic Colorectal Cancer Patients
Cancer Research and Treatment. 2019;51(3):1128-1134   Crossref logo
Link1 Link2 Link3

616 POSTER Safety analysis of first-line bevacizumab plus chemotherapy in patients with metastatic colorectal cancer (mCRC) participating in a US registry
European Journal of Cancer Supplements. 2005;3(2):173   Crossref logo
Link1 Link2

Chronomodulated administration of oxaliplatin plus capecitabine (XELOX) as first line chemotherapy in advanced colorectal cancer patients: phase II study
Cancer Chemotherapy and Pharmacology. 2006;59(5):613-620   Crossref logo
Link1 Link2 Link3

FOLFIRI plus bevacizumab as a first-line treatment for Japanese patients with metastatic colorectal cancer: a JACCRO CC-03 multicenter phase II study
Cancer Chemotherapy and Pharmacology. 2013;72(5):1097-1102   Crossref logo
Link1 Link2 Link3

Commentary on a Phase III Trial of Bevacizumab plus XELOX or FOLFOX4 for First-Line Treatment of Metastatic Colorectal Cancer: The NO16966 Trial
Clinical Colorectal Cancer. 2006;6(4):261-264   Crossref logo
Link1 Link2

XELOX and bevacizumab followed by single-agent bevacizumab as maintenance therapy as first-line treatment in elderly patients with advanced colorectal cancer: the boxe study
Cancer Chemotherapy and Pharmacology. 2012;71(1):257-264   Crossref logo
Link1 Link2 Link3

Cetuximab plus XELIRI or XELOX for First-Line Therapy of Metastatic Colorectal Cancer
Clinical Colorectal Cancer. 2008;7(2):110-117   Crossref logo
Link1 Link2

Skin toxicity and quality of life in patients with metastatic colorectal cancer during first-line panitumumab plus FOLFIRI treatment in a single-arm phase II study
BMC Cancer. 2012;12(1):   Crossref logo
Link1 Link2 Link3

P-206Prognostic factors of metastatic colorectal cancer patients undergoing first-line chemotherapy plus bevacizumab
Annals of Oncology. 2019;30(Supplement_4):   Crossref logo
Link1

A Phase II Study of XELOX and Cetuximab as First-Line Therapy in Patients With KRAS Wild Type Metastatic Colorectal Cancer (FLEET2 Study)
Clinical Colorectal Cancer. 2016;15(4):329-336   Crossref logo
Link1 Link2

This metadata service is kindly provided by CrossRef from May 29, 2014. Cancer Res Treat has participated in CrossRef Text and Data Mining service since October 29, 2014.